Status: Finalised
First registered on:
03/04/2020
Last updated on:
11/05/2020
1. Study identification
EU PAS Register NumberEUPAS34541
Official titleAssociation of ACE inhibitors and AT1R blockers and prognosis in hospitalized COVID-19 patients: a cohort study in Italy
Study title acronymITA-COVID: RAS INHIBITORS
Study typeObservational study
Brief description of the studyThis observational study will use Italian claims databases from 5 catchment areas (Lombardy, Veneto and Lazio Regions as well as Modena and Reggio Emilia Local Health Unit) linked to COVID-19 patient registries in the same catchment areas. The aim of the study is to evaluate whether treatment with ACE-inhibitors or angiotension receptor blockers modifies the clinical progression or prognosis of patients infected with COVID-19 who have been hospitalised.
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research groupPharmacoepidemiology Unit - National Centre for Drug Research and Evaluation
Organisation/affiliationIstituto Superiore di Sanità (ISS)
Details of (Primary) lead investigator
Title Dr
Last name Spila Alegiani
First name Stefania
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Multiple centres
In total how many centres are involved in this Study?5
Countries in which this study is being conducted
National study
Italy
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed31/03/202031/03/2020
Start date of data collection15/04/202031/03/2020
Start date of data analysis
Date of interim report, if expected15/05/2020
Date of final study report30/05/202030/04/2020
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government body
Research councils
EU funding scheme
OtherSelf-funded100
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Trifirò
First name Gianluca
Address line 11, Via Consolare Valeria
Address line 2BIOMORF Dept. University of Messina
Address line 3
CityMessina
Postcode98125
CountryItaly
Phone number (incl. country code)390902213264
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Professor
Last name Trifirò
First name Gianluca
Address line 11, Via Consolare Valeria
Address line 2BIOMORF Dept. University of Messina
Address line 3
CityMessina
Postcode98125
CountryItaly
Phone number (incl. country code)390902213264
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)C09 (AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM)
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects21000000
10. Source of data
Is this study being carried out with an established data source?No
Sources of data
Disease/case registry
Administrative database, e.g. claims database
11. Scope of the study
What is the scope of the study?
Disease epidemiology
Risk assessment
Drug utilisation study
Primary scope : Risk assessment
12. Main objective(s)
What is the main objective of the study?
The aim of this study is to verify if the use of ACE inhibitors and/or angiotensin receptor blockers before COVID-19 outbreak may modify the clinical course of infection and prognosis of hospitalized SARS-CoV-2 infected patients in Italy.
Are there primary outcomes?Yes
Death, intensive care unit (ICU) admission, and length of ICU stay.
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
Patients will be followed up as long as they are alive and registered within the regional NHS of the catchment area from which they were originally identified.
15. Data analysis plan
Please provide a brief summary of the analysis method
Data will be described using frequencies, percentage, mean with standard deviations (or median with interquartile range, where appropriate). The association between ACE inhibitors and/or AT1R blockers and the study outcomes will be analyzed.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
18. Study Results
Not submitted
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
